Element Materials Technology has completed its sixth life sciences focused deal of 2021 through its acquisition of JMI Laboratories, a provider of antimicrobial resistance monitoring studies for new drug applications.
The deal allows Element the expertise and capability for pharmaceutical and biopharmaceutical customers. The firm will expand to a team of over 1,000 experts across 23 facilities. JMI provides microbiology and molecular testing services to aid in the development of antimicrobials and clinical trial support.
“In a world still dealing with a pandemic, the life sciences sector has never been more vital,” stated Cherie Gudz, vice president, Life Sciences America. “The six acquisitions this past year alone cements Element’s commitment to continue to build a scale business in this vital sector, which now forms our largest global end-market. We are thrilled to have JMI’s team and expertise join the Element family.”
“Our expansion into life sciences and connected technologies over the last two years has seen us gain a leadership position in these strategically important end-markets,” added Jo Wentz, Element CEO. “As we celebrate 10 years of being a standalone Element business, we see more and more opportunities to work closely with our customers throughout their product and testing lifecycles.”